BNT-114 is a mRNA Vaccine owned by BioNTech, and is involved in 1 clinical trial, which is ongoing.

BNT-114 elicits an immune response directed against tumor antigens to help fight off residual tumor cells. The therapeutic candidate delivers mRNA encoding patient-specific antibody to induce antigen-expression. Immune system recognize tumor antigens as foreign organism and release the antibodies to counter their entry into the body and kills caner cells expressing the antigen.

The revenue for BNT-114 is expected to reach a total of $65m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the BNT-114 NPV Report.

BNT-114 was originated by University Medical Center of Johannes Gutenberg University Mainz and BioNTech and is currently owned by BioNTech.

BNT-114 Overview

BNT-114 is under development for the treatment of triple negative breast cancer. The therapeutic candidate is administered through intravenous route. It is developed based on messenger RNA (mRNA) therapeutics technology, which enables delivery of mRNA complexed with liposome.

BioNTech Overview

BioNTech is a biotechnology company that develops immunotherapies for cancer and infectious diseases. It is investigating mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators to treat advanced melanoma, solid tumors, non-small cell lung cancer (NSCLC), prostate, head and neck, ovarian, pancreatic and triple negative breast cancer. The company is also evaluating treatments for HIV, tuberculosis, influenza and covid-19. BioNTech utilizes FixVac and iNeST technology platforms to discover and develop cancer immunotherapies targeting antigens and neoantigens. It works in partnership with Genentech Inc, Eli Lilly and Co, Genmab AS, and other biopharmaceutical companies to develop its pipeline products. BioNTech is headquartered in Mainz, Rhineland-Palatinate, Germany.

The company reported revenues of (Euro) EUR18,976.7 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of EUR482.3 million in FY2020. The operating profit of the company was EUR15,283.8 million in FY2021, compared to an operating loss of EUR82.4 million in FY2020. In FY2021, the company recorded a net margin of 54.2%, compared to a net margin of 3.2% in FY2020. The company reported revenues of EUR3,461.2 million for the third quarter ended September 2022, an increase of 8.3% over the previous quarter.

Quick View – BNT-114

Report Segments
  • Innovator
Drug Name
  • BNT-114
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.